Clinical Trials Browser

INDUSTRY × romidepsin × Dermatologic × Clear all

NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Phase 2 Completed

102 enrolled 15 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous